Least Developed Countries (LDCs) vs Pakistan: Percentage of bloodstream infection due to Escherichia coli resistant
Least Developed Countries (LDCs)
73.5%
in 2022
Pakistan
83.5%
in 2022
Least Developed Countries (LDCs) rank
4th
Pakistan rank
1st
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Least Developed Countries (LDCs)
- Pakistan
How they compare
Pakistan currently reports 83.5% against 73.5% in Least Developed Countries (LDCs), a difference of 10.0%.
That makes Pakistan's figure about 1.1 times Least Developed Countries (LDCs)'s.
Across all 6 years both countries report, Pakistan has been ahead every year.
Least Developed Countries (LDCs) ranks 4th and Pakistan ranks 1st of 16 groups.
Pakistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Least Developed Countries (LDCs) | Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 51.7% | 81.4% | 29.7% | Pakistan |
| 2020s | 72.7% | 83.7% | 10.9% | Pakistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Least Developed Countries (LDCs) or Pakistan?
- Pakistan, at 83.5% against 73.5% in Least Developed Countries (LDCs) as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Least Developed Countries (LDCs) and Pakistan?
- 10.0%, with Pakistan ahead.
- How many years of comparable data are there for Least Developed Countries (LDCs) and Pakistan?
- 6 years are reported by both, from 2017 to 2022.
- How do Least Developed Countries (LDCs) and Pakistan rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Least Developed Countries (LDCs) ranks 4th and Pakistan ranks 1st of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.